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Abstract 
Mice with a constitutive or tamoxifen-induced Cre recombinase (Cre) expression are 
frequently used research tools to allow the conditional deletion of target genes via the Cre-
loxP system. Here we analyzed for the first time in a comprehensive and comparative way, 
whether retinal Cre expression or topical tamoxifen treatment itself would cause structural or 
functional changes, including changes in the expression profiles of molecular markers, glial 
reactivity and photoreceptor vulnerability. To this end, we characterized the transgenic α-Cre, 
Lmop-Cre and the tamoxifen inducible CAGG-CreERTM mouse lines, all having robust Cre 
expression in the neuronal retina. In addition, we characterized the effects of topical 
tamoxifen treatment itself in wildtype mice. We performed morphometric analyses, 
immunohistochemical staining, in vivo ERG and angiography analyses and realtime RT-PCR 
analyses. Furthermore, the influence of Cre recombinase or topical tamoxifen exposure on 
neuronal vulnerability was studied by using light damage as a model for photoreceptor 
degeneration. Taken together, neither the expression of Cre, nor topical tamoxifen treatment 
caused detectable changes in retinal structure and function, the expression profiles of 
investigated molecular markers, glial reactivity and photoreceptor vulnerability. We conclude 
that the Cre-loxP system and its induction through tamoxifen is a safe and reliable method to 
delete desired target genes in the neural retina. 
  
  
Introduction 
The Cre-loxP system is widely used to conditionally delete target genes [1]. This allows 
circumventing potential embryonic lethality that would result from a constitutive deletion of 
essential target genes. A critical element of this system is the Cre recombinase, a nuclease 
encoded by the Cre gene of the bacteriophage P1 [2]. Over the last years, the Cre-loxP 
based technique has greatly expanded through the availability of Cre expressing mice in 
which expression is either controlled through cell- or tissue- specific promotor elements, or 
inducible by administration of certain drugs [3,4]. Still, there is growing concern that the 
expression of a protein originating from a different organism might itself, directly or indirectly, 
interfere with the cellular homeostasis of the targeted tissue or the targeted cell population. 
Publications showing that the expression of Cre might cause chromosomal rearrangements, 
growth arrest or influence gene expression profiles [5–7] provided first indications for these 
unwanted side effects. Furthermore, there is data showing that the expression of Cre 
resulted in the degeneration of neurons e.g. photoreceptor cells accompanied by an impaired 
neuronal function [8]. Moreover, when using drug based inducible systems, the application of 
drugs such as tamoxifen can have unwanted side effects, too. In support of this Kim and 
coworkers reported that tamoxifen exposure leads to cell death of retinal pigment epithelial 
(RPE) cells through caspase dependent and independent mechanisms [9].  
In the current study we investigated the influence of Cre recombinase expression and topical 
tamoxifen exposure to neuronal tissues, with the murine retina as an easily accessible model 
system. For the first time, this study shows comprehensive and comparative data, 
addressing the retinal morphology and function, glial reactivity, the molecular expression 
levels of neuroprotective factors, as well as neuronal vulnerability following light induced 
photoreceptor degeneration. We analyzed three different, widely used transgenic Cre 
expressing mouse strains and compared Cre expressing or tamoxifen-exposed retinae to 
control retinae. We used the α-Cre line, the Lmop-Cre line and the tamoxifen inducible 
CAGGCre-ERTM line [10–12], all of them having a robust expression of Cre in the entire 
retina, or certain cellular subpopulations of the retina. In summary, we did not observe Cre 
  
recombinase or tamoxifen induced changes in retinal structure and function, glial reactivity, 
expression of neuroprotective factors or photoreceptor vulnerability in any of the models 
investigated. 
Material and Methods 
Mice 
All procedures conformed to the tenets of the National Institutes of Health Guidelines on the 
Care and Use of Animals in Research, the EU Directive 2010/63/E, and institutional 
guidelines. All mice were albino, homozygous for the L450 variant of RPE65 [13] and reared 
in 12 h light–12 h dark cycles (lights on at 7 am). Transgenic CAGGCre-ERTM [11] and α-Cre 
[10] mice were bred in a mixed FVB/N × Balb-c background (F1) and Lmop-Cre [12] were 
bred in a CD1 x Balb-c background.  
Tamoxifen treatment 
The Cre recombinase in transgenic CAGGCre-ERTM is inducible. These mice carry the Cre-
ERTM fusion protein comprised of the Cre-recombinase protein fused to a mutant form of the 
mouse estrogen receptor [11]. The fusion protein is restricted to the cytoplasm and Cre-ERTM 
will only access the nucleus after binding to tamoxifen. We additionally used Balb-c wildtype 
animals to analyze the influence of tamoxifen treatment only. To this end, tamoxifen 
(Cayman Chemicals, Ann Arbor, MI, USA) was diluted in corn oil (Sigma-Aldrich Chemie 
GmbH, Munich, Germany) to a final concentration of 5 mg/ml and the solution was topically 
applied as eye drops (10 µl/drop) onto the eyes of CAGGCre-ERTM mice and control 
littermates or Balb-c wildtypes, respectively, three times per day in four hours intervals as 
described previously [14,15]. Our treatment started at postnatal day (P) 28 and lasted to P32. 
As a side note regarding the use of tamoxifen: we used tamoxifen, not 4OH-tamoxifen, to 
activate the Cre recombinase in CAGGCre-ERTM animals. Tamoxifen binds to the mutant 
form of the mouse estrogen receptor with lower affinity than 4OH-tamoxifen [16,17]. 
However, due to the topical application, very high local concentrations are reached, resulting 
  
in a successful activation of the Cre recombinase in these animals, as can be seen in Fig. 1 
and [11,14,15].  
PCR analyses for genotyping  
Genotypes were screened by isolating genomic DNA from tail biopsies and testing for 
transgenic sequences by PCR as described previously [18]. For detection of Cre primer 
sequences were 5’-ATG CTT CTG TCC GTT TGC CG-3' (sense) and 5'-CCT GTT TTG CAC 
GTT CAC CG-3' (antisense) and for lacZ genotyping the primer sequences were 5'-ATC CTC 
TGC ATG GTC AGG TC-3' (sense) and 5'-CGT GGC CTG ATT CAT TCC-3' (antisense). 
The thermal cycle profile was denaturation at 96°C for 30 s, annealing at 57°C (Cre) or 60°C 
(lacZ) for 30 s, and extension at 72°C for 35 s for 35 cycles.  
β-galactosidase staining 
Heterozygous CAGGCre-ERTM, α-Cre or Lmop-Cre mice were crossed with homozygous 
Cre-reporter (R26R) mice (genetic background: 129SV) [19]. The resulting CAGGCre-ERTM 
(or α-Cre or Lmop-Cre)/R26R mice were used as experimental mice, and R26R littermates 
as control mice. Lac-Z-staining was performed in mixed CAGGCre-ERTM (or α-Cre or 
Lmop-Cre)/R26R and R26R mice following a previously published protocol [18]. Paraffin 
sections (6 µm thick) were analyzed using an Axio Imager Z1 light microscope (Carl Zeiss 
Microscopy GmbH, Jena, Germany) and the appropriate Axiovision software 4.8 (Carl Zeiss 
Microscopy GmbH, Jena, Germany). 
Microscopy and morphometry 
Eyes were isolated, post-fixed for 24 h in modified Karnovsky fixative [20] and embedded in 
Epon (SERVA Electrophoresis GmbH, Heidelberg, Germany). Semithin sagittal sections (1.0 
µm thick) were cut through the eyes and stained after Richardson [21]. Sagittal sections were 
investigated using an Axio Imager Z1 fluorescent microscope (Carl Zeiss Microscopy GmbH, 
Jena, Germany) and the appropriate Axiovision software 4.8 (Carl Zeiss Microscopy GmbH, 
Jena, Germany). Thickness of the outer nuclear layer (ONL) and inner nuclear layer (INL) 
were measured on semithin sections along the mid-horizontal (nasal-temporal) plane. Briefly, 
  
the distance between ora serrata (OS) and optic nerve head (ONH) was divided into tenths 
to defined individual measure points. We measured one section per animal and one 
measurement (INL and ONL) per measure point. The sections were always stretching 
through the optic nerve head to ensure comparable conditions between the individual 
sections. Subsequently, ONL or INL thickness was measured at these measure points and 
the means± SEM of the ONL or INL thickness were plotted in a spider diagram as described 
in [18,22].  
Immunohistochemistry 
Prior to GFAP staining, eyes were fixed for 4 h in 4% paraformaldehyde (PFA), washed 
extensively in phosphate buffer (PB, 0.1 M sodium phosphate, pH 7.4) and embedded in 
paraffin according to standard protocols. Paraffin sections (6 µm) were deparaffinized and 
washed in H2O. IBA-1 immunohistochemistry was performed on frozen sections. Eyes were 
fixed for 4 h in 10% glacial acetic acid, 60% methanol and 30% chloroform. Eyes were 
consecutively washed with 50%, 25% methanol and PB for 30 min each and incubated for 
several hours in each 10%, 20% and 30% sucrose/PB at 4°C. Finally, samples were rapidly 
frozen in tissue mounting medium (DiaTec, Bamberg, Germany). For IBA-1 
immunohistochemistry, the sections were pre-treated with 0.2 M NH4Cl for 30 min to 
minimize potential unspecific background staining, then washed three times in PB for 5 min 
each and incubated in Triton-X100 for 5 min. All sections were washed three times in PB for 
5 min each and blocked with 2% BSA/0.1% Triton in PB for 45 min at room temperature. 
Primary antibodies (GFAP (Dako Deutschland GmbH, Hamburg, Germany) 1:1000, IBA-1 
(Wako Chemicals GmbH, Neuss, Germany) 1:500) were diluted in a 1:10 dilution of the 
blocking solution in PB and incubated at 4°C overnight. To test for the specificity of the 
antibody, negative control sections were incubated with the 1:10 dilution of the blocking 
solution only. After three 5 min PB buffer wash steps, the sections were incubated for 1 h 
with secondary antibodies (GFAP: anti-rabbit Alexa 546 (Thermo Fisher Scientific, Waltham, 
MA USA) 1:1000 or IBA-1: anti-rabbit CyTM-3 conjugated (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA) 1:2000) in blocking solution 1:10 diluted in PB. 
  
Sections were washed three times in PB and cell nuclei were counterstained with DAPI 
(Vector Laboratories, Inc., Burlingame, CA, USA, final concentration of 0.15 µg/ml) in Moviol 
fluorescent mounting medium.  
Electroretinography 
Mice were dark adapted for at least 12 h before experiments and anesthetized by s.c. 
injection of ketamine (65 mg/kg) and xylazine (13 mg/kg). Pupils were dilated with 
tropicamide eyedrops (Mydriaticum Stulln; Pharma Stulln GmbH, Stulln, Germany). Silver 
needle electrodes served as reference (forehead) and ground (tail) and gold wire ring 
electrodes as active electrodes. Corneregel (Bausch & Lomb GmbH, Berlin, Germany) was 
applied to keep the eye hydrated and to maintain good electrical contact. ERGs were 
recorded using a Ganzfeld bowl (Ganzfeld QC450 SCX, Roland Consult, Stasche & Finger 
GmbH, Brandenburg a.d.Havel, Germany) and an amplifier & recording unit (RETI-Port, 
Roland Consult, Stasche & Finger GmbH, Brandenburg a.d.Havel, Germany). ERGs were 
recorded from both eyes simultaneously, band-pass filtered (1 to 300 Hz) and averaged. 
Single flash scotopic (dark adapted) responses to a series of ten LED-flash intensities 
ranging from -3.5 to 1.0 log cd.s/m2 with an inter stimulus interval of 2 up to 20 seconds for 
the highest intensity were recorded. After 10 minutes of adaptation to a white background 
illumination (20 cd/m2) single flash photopic (light adapted) responses to three Xenon-flash 
intensities (1, 1,5 and 2 log cds/m2) were recorded. All analysis and plotting was carried out 
with R 3.2.1 (The R Foundation for Statistical Computing) and ggplot2 1.0.1 [23]. 
Fundus imaging and angiography 
Retinal imaging was performed with a commercially available imaging system (Micron III; 
Phoenix Research Labs, Pleasanton, CA, USA). Light source path and imaging path filters 
(low pass and high pass at 500 nm) were used for fluorescein angiography (FLA). Mice were 
anesthetized by s. c. injection of ketamine (65 mg/kg) and xylazine (13 mg/kg), and their 
pupils were dilated with tropicamide eyedrops (Mydriaticum Stulln; Pharma Stulln GmbH, 
  
Stulln, Germany) before image acquisition. FLA was performed using a s.c. injection of 75 
mg/kg body weight fluorescein-Na (ALCON Pharma GmbH, Freiburg, Germany). 
RNA analysis 
Total RNA from neural retinae was extracted using TRIzol and first strand cDNA synthesis 
was performed using iScript cDNA Synthesis Kit (Bio-Rad Laboratories GmbH, Munich, 
Germany) according to manufacturer’s instructions. Quantitative real-time RT-PCR analyses 
were performed using the Bio-Rad iQ5 Real-Time PCR Detection System (Bio-Rad 
Laboratories GmbH, Munich, Germany). The temperature profile was denaturation at 95°C 
for 10 seconds and annealing and extension at 60°C for 40 seconds for 40 cycles. All primer 
pairs were purchased from Invitrogen and extended over exon–intron boundaries, except for 
Gapdh. Sequences of primer pairs are shown in table 1. RNA that was not reverse 
transcribed served as negative control for real-time RT-PCR. Three different potential 
housekeeping genes were tested: glyceraldehyde 3-phosphate dehydrogenase (Gapdh), 
guanine nucleotide binding protein (Gnb2l), and ribosomal protein L32 (Rpl32). After 
statistical evaluation of the different housekeepers, the geo mean of the housekeeping genes 
was used for relative quantification of retinae samples. Quantification was performed using 
BioRad iQ5 Standard-Edition (Version 2.1) software (Bio-Rad Laboratories GmbH, Munich, 
Germany) and the ∆∆Ct method in Excel (Microsoft Corporation, Redmond, WA, USA) [24]. 
Light damage 
To experimentally induce the apoptosis of photoreceptor cells [25–27], six to seven weeks 
old albino mice that were homozygous for the L450 variant of RPE65 [13] were transferred to 
cyclic dim light (<100 lux) for 5 d followed by a a dark-adapting period of 12 h. Mice were 
then placed in reflective cages and exposed to diffuse cool, white fluorescent light coming 
from the top of the cage with an intensity of 5000 lux for 30 min. Average intensity was 
measured on the cage floor (5000 lux). After light exposure, mice were allowed to recover 
first for 6 h in dim light and then brought back to normal cyclic light conditions before 
sacrifice. Light damage experiments were always performed in the early morning. 
  
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)  
Apoptotic cell death was analyzed by TUNEL labeling using the Apoptosis Detection System 
(DeadEnd Fluorometric TUNEL, Promega GmbH, Mannheim, Germany). Paraffin sections 
were treated following manufacturers’ instructions and protocols reported previously [18]. For 
quantitative analysis, the number of TUNEL-positive nuclei in sagittal sections throughout the 
entire retina was counted using the ImageJ software program and normalized to the area of 
the ONL [18,28]. 
Statistical analysis 
All results are expressed as mean ± standard error of the mean (SEM). Statistical 
significance was calculated by using a two-tailed Student’s t-test. P values ≤ 0.05 were 
considered to be statistically significant. 
Results 
To elucidate the potential influence of Cre recombinase expression or topical tamoxifen 
exposure on the neuronal retina, we compared four groups of mice: (1) Tamoxifen treated 
wildtype animals (control(TX)) were compared to their untreated wildtype littermates 
(control). (2) Tamoxifen treated transgenic CAGGCre-ERTM animals (CAGGCre-ERTM) were 
compared to equally tamoxifen treated wildtype littermates (control(TX)). (3) Transgenic α-
Cre animals (α-Cre) were compared to wildtype littermates (control) and (4) Lmop-Cre 
animals (Lmop-Cre) were compared to wildtype littermates (control). 
Cre recombinase expression and activity 
CAGGCre-ERTM/R26R mice carry a Cre-ERTM fusion protein comprised of the Cre 
recombinase protein fused to a mutant form of the mouse estrogen receptor [11]. The fusion 
protein is restricted to the cytoplasm and Cre-ERTM will only translocate to the nucleus after 
binding to tamoxifen. In transgenic α-Cre mice, the Cre recombinase is expressed under the 
control of the α-enhancer element of the pax6 promotor resulting in an early (embryonic day 
10.5) and constitutive expression of Cre in all cells that originate from the inner layer of the 
optic cup [10]. In transgenic Lmop-Cre animals, the Cre recombinase is constitutively 
  
expressed under the control of the murine opsin promotor [12]. Promotor activity starts with a 
rather weak expression from postnatal day 7, until Cre expression reaches gradually its 
maximum approximately at the age of six weeks [12]. We used the R26R Cre reporter mice 
to confirm and to visualize the activity of the Cre recombinase in all three analyzed 
transgenic Cre expressing mouse lines. In the R26R mouse line, a loxP-flanked DNA 
segment prevents the expression of a downstream lacZ gene. Consequently, when R26R 
mice are crossed to a Cre expressing transgenic mouse line, Cre expression leads to the 
removal of the loxP-flanked DNA segment resulting in the expression of the lacZ protein in all 
cells in which Cre had been expressed. Using β-galactosidase staining one can directly 
visualize the cell population in which Cre recombinase had been active [19]. In CAGGCre-
ERTM Cre mice, we observed β-galactosidase staining, indicating lacZ reactivity, throughout 
the eyes of four weeks old CAGGCre-ERTM/R26R animals after tamoxifen treatment (Fig.1A). 
Notably, in the retina all neuronal layers were stained, as was the retinal pigment epithelium 
and the adjacent choroid (Fig. 1A). The control(TX)/R26R littermates did not show any lacZ 
reaction in the eye, confirming the specificity of the performed β-galactosidase staining. 
When lacZ staining was performed in 10 days old transgenic α-Cre mice, the β-galactosidase 
reaction was restricted to the neuronal layers of the retina and the non-pigmented epithelial 
layer of the ciliary body and iris while the control/R26R animal did not show any lacZ reaction 
(Fig. 1B). As expected, in Lmop-Cre animals, β-galactosidase staining was restricted to the 
outer plexiform layer, the inner and outer segments of the photoreceptors and appeared 
rather patchy in the outer nuclear layer at the age of three weeks (Fig. 1C). Again, the 
control/R26R animals did not show any β-galactosidase staining (Fig. 1C). 
Cre recombinase expression or tamoxifen treatment do not change retinal morphology and 
function 
To investigate, whether the expression of Cre or topical tamoxifen exposure might influence 
retinal morphology, we analyzed semithin section of six to ten weeks old animals. We did not 
observe overt structural differences in any of the three investigated transgenic Cre 
expressing mouse lines (CAGGCre-ERTM, α-Cre line and Lmop-Cre line), nor in the 
  
tamoxifen treated control(TX) animals, compared to their respective controls. All investigated 
eyes were well developed and showed a regular neuronal architecture (Fig. 2A, D, G, J), as 
well as a regular retinal vasculature, determined by in vivo fluorescence angiography (Fig 3A, 
B, C). To conduct a detailed morphometric analysis, we measured the thickness of the inner 
nuclear layer (INL) and the outer nuclear layer (ONL). The mean values of the thickness at 
individual measure points were plotted in a spider diagram followed by statistical evaluation. 
Here, we could not detect any statistically significant differences between experimental (Cre 
expressing and/or tamoxifen-treated) and control mice (INL: Fig. 2B, E, H, K; ONL: Fig. 2C, 
F, I, L). When investigating retinal function by ERG analysis, we focused on the CAGGCre-
ERTM line, as this mouse line showed the most robust expression of Cre in the entire retina 
following tamoxifen treatment. Here, we could not detect any statistically significant 
differences between CAGGCre-ERTM animals and their control(TX) littermates (Fig. 4). ERG 
analyses showed similar waveforms for both, the dark and light adapted responses of the 
CAGGCre-ERTM and control(TX) animals (Fig. 4). The a- and b-wave amplitudes (Fig. 4A 
and B) and implicit times (Fig. 4C) were similar for all flash strengths of the dark adapted 
ERG responses indicating a regular rod function. Transgenic CAGGCre-ERTM mice showed 
similar waveforms (Fig. 4D) and amplitudes (Fig. 4E) compared to control(TX) littermates for 
the light adapted ERG responses. The small differences in implicit times (Fig. 4E) were not 
statistically significant, indicating a normal cone function. In summary, these findings showed 
that the ectopic expression of Cre or topical tamoxifen treatment neither changes retinal 
morphology nor do they interfere with retinal function.  
Cre recombinase expression or tamoxifen treatment do not induce macro- and microglia 
reactivity 
Next we investigated, whether the expression of Cre or tamoxifen exposure might cause 
reactive changes in the retinal microglia. To this end, we performed immunohistochemistry 
using an antibody against ionized calcium binding adaptor molecule 1 (IBA1) to visualize the 
retinal microglial cells [29]. We did not observe any obvious structural changes in the 
morphological appearance of the microglia cells that would indicate a switch from a resting to 
  
a reactive phenotype [14,30,31] when comparing microglial cells of Cre expressing mice to 
their respective wildtype littermates. In CAGGCre-ERTM, α-Cre, Lmop-Cre, tamoxifen treated 
control(TX) animals and wildtype mice, IBA1-positive microglia cells showed a ramified 
morphology with the characteristic localization of these cells in the inner and outer plexiform 
layers and the retinal ganglion cell layer (Fig. 5A, C, D), which indicates a resting microglia 
cell population. Finally, we analyzed the retinae of CAGGCre-ERTM mice and their control 
littermates for markers of microglial reactivity. We restricted the analysis to the CAGGCre-
ERTM mice as this is the only Cre line in our study, in which the microglial cells could be 
directly affected by the expression of Cre recombinase. However, we could not detect any 
statistically significant differences in the expression levels of the investigated molecular 
markers (Cd68, Iba1, Egr1 and Ccl2) of CAGGCre-ERTM retinae, compared to control(TX) 
retinae (Fig. 5B). Furthermore, we did not observe any statistically significant differences 
comparing control retinae to tamoxifen treated control(TX) retinae (Fig. 5B). To exclude the 
possibility that expression of Cre or tamoxifen exposure would result in reactivity of Müller 
cells or astrocytes, we used immunohistochemical staining for glial fibrillary acidic marker 
protein (GFAP). Since mature retinal astrocytes do express GFAP [32,33], we observed an 
intense immunoreactivity for GFAP in the RGC layer, exactly where the retinal astrocytes are 
located. However, the overall intensity of GFAP and the astrocyte cell morphology did not 
differ between control or transgenic animals, indicating the resting astrocyte population 
[33,34]. Furthermore, we did not detect the characteristic radial stripes throughout the retina 
that would indicate a reactivity of Müller cells (Fig. 6A, C, E) [35]. Moreover, we used realtime 
RT-PCR analysis to screen the retinae for Gfap mRNA expression levels, but we did not 
detect any significant differences in its expression levels (Fig. 6B, D, F). Fig. 6B, CAGGCre-
ERTM line, control(TX): 1 ± 0.35, CAGGCre-ERTM: 1.04 ± 0.19 (p = 0.91); Fig. 6D, α-Cre line, 
control: 1 ± 0.33, α-Cre: 0.78 ± 0.08 (p = 0.58); Fig. 6F, Lmop-Cre line: control: 1 ± 0.19, 
Lmop-Cre: 0.87 ± 0.14 (p = 0.59) and tamoxifen exposed control(TX) retinae, control: 1 ± 
0.38, control(TX): 0.88 ± 0.38 (n = 5/5, p = 0.83). Taken together, the ectopic expression of 
  
Cre and/or tamoxifen exposure did not result in reactive changes of retinal macro- or 
microglial cells. 
Cre recombinase expression or tamoxifen treatment do not influence the expression of 
neuroprotective factors 
Next, we analyzed whether the expression of Cre or tamoxifen exposure might interfere with 
the expression levels of certain neuroprotective factors. Here we focused on leukemia 
inhibitory factor (Lif), endothelin 2 (Edn2) and fibroblast growth factor 2 (Fgf2), as these 
factors are well known to play a major role in retinal neuroprotective signaling cascades [36–
39]. Using realtime RT-PCR analysis we could not detect any significant differences in the 
expression levels of the investigated factors in all three transgenic Cre mouse strains 
(CAGGCre-ERTM, α-Cre line and Lmop-Cre line) compared to their control littermates (Fig. 
7A, C, D). Furthermore, we did not observe any statistically significant differences when 
control retinae were compared with tamoxifen treated control(TX) retinae (Fig. 7B).  
Cre recombinase expression or tamoxifen treatment do not alter neuronal vulnerability  
We next examined whether the expression of Cre or tamoxifen exposure might have an 
influence on the vulnerability of neurons following experimentally induced damage. Here we 
focused on the photoreceptor cells and used the light damage as a model to induce 
photoreceptor degeneration through apoptosis. We labeled the apoptotic photoreceptor cells 
in the light exposed animals by using the ‘terminal deoxynucleotidyl transferase dUTP nick 
end labeling’ (TUNEL) method (Fig. 8). Subsequently, we counted the total number of 
TUNEL positive cells and normalized this number to the area of the ONL (Fig. 8C, F, I). In 
the following statistical evaluation, we could not detect any statistically significant differences 
between the transgenic lines (CAGGCre-ERTM line, control(TX): 1 ± 0.32, CAGGCre-ERTM: 
0.81 ± 0.23 (p = 0.63); α-Cre line, control: 1 ± 0.10, α-Cre: 1.16 ± 0.11 (p = 0.74); Lmop-Cre 
line, control: 1 ± 0.22, Lmop-Cre: 0.86 ± 0.14 (p = 0.66)), the tamoxifen exposed animals 
(control: 1 ± 0.16, control(TX): 0.67 ± 0.11 (n = 4/5, p = 0.13)) and the corresponding 
controls. 
  
Discussion 
For the first time, our study addresses the long standing discussion whether expression of 
Cre recombinase or tamoxifen exposure itself might alter neuronal vulnerability. In the light of 
our results, we conclude that neither the ectopic expression of Cre recombinase, nor topical 
tamoxifen exposure via eye drops affect structure or function of the neuronal retina. This 
conclusion is based on the findings that neither the retinal morphology, nor function was 
different in control animals compared to transgenic Cre expressing animals from three 
different mouse lines. The same was true for the comparison of control animals to tamoxifen 
exposed animals. Furthermore, no changes were observed in macro- and microglial cell 
reactivity and glial marker expression patterns. Finally, we could neither detect differences in 
the mRNA expression levels of several neuroprotective factors, nor did we detect any 
changes in photoreceptor vulnerability, whether Cre recombinase or tamoxifen was present 
or not.  
Our study characterizes potential side effects of Cre expression or its nuclear translocation, 
in the case of the CAGGCre-ERTM mouse, to the retina. Formally, we cannot exclude 
potential side effects arising of a Cre-mediated recombination in the genomic DNA. Our 
results regarding retinal morphology and morphometry are in line with previously reported 
observations by Le and coworkers, who also showed that these parameters were not altered 
in Lmop-Cre animals [40]. However, we included two additional transgenic mouse lines with 
an even more pronounced retinal expression of Cre: the α-Cre [10] and the tamoxifen 
inducible CAGGCre-ERTM mouse line [11] and characterized all lines in a comprehensive and 
comparative way. Additionally, we characterized the retinal vasculature using in vivo 
fluorescence angiography and analyzed the expression profiles of molecular markers and 
changes in photoreceptor vulnerability for all three mouse lines and after tamoxifen 
treatment. Furthermore, we studied the potential effects on glial cells in the retina.  
Neither tamoxifen exposure, nor the presence of Cre recombinase led to any detectable 
changes in reactivity of macro- or microglial cells, important components of the retinal innate 
  
immune system [30,35,41–43]. In conclusion, Cre recombinase, an exogenous protein, does 
not provide an immunological challenge if translated in mouse cells. Müller cell reactivity or 
gliosis is one of the earliest and most sensitive markers of retinal damage [35,44]. The 
absence of typical parameters of the Müller cell gliosis reaction like an increase in GFAP 
expression strongly supports the concept that the retinal presence of Cre recombinase 
and/or tamoxifen exposure do not interfere with structure and function of retinal cells. 
However, the eye is an immune privileged organ with a high level of transforming growth 
factor (TGF)-β2, contributing to the quiescence of microglia and Müller cells [30,42,43,45,46]. 
This raises the possibility that the high level of TGF-β2 counteracts a potential cellular 
reactivity of these cells upon the ectopic expression of Cre or tamoxifen exposure. 
Consequently, we cannot exclude the possibility that this situation might be different in other, 
less immune-privileged organs. Our group and others recently showed that upon Müller cells 
reactivity, as evidenced by elevated expression levels of Gfap, the mRNA levels of 
neuroprotective factors like Edn2, Lif and Fgf2 were induced in the retina [27,44,47–49]. In 
this study, however, we did not observe changes in Gfap levels and conclusively we could 
also not detect any statistically significant differences in the expression of these factors, 
whether Cre or tamoxifen exposure was present or not.  
The expression of Cre recombinase might pose especially problematic for photoreceptors, 
because they are more prone to become apoptotic as soon as their cellular homeostasis is 
disturbed. This could be due to genetic disease mutations [50,51], or the expression of a 
foreign protein like Cre. Moreover, there is accumulating evidence that the expression of 
mutated or exogenous proteins in glial cells, resulting in dysregulated glial cell function, can 
increase the vulnerability of neuronal cells (see for example [52–54]). This gives rise to the 
possibility that the ectopic expression of Cre in neurons or glial cells might also increase the 
vulnerability of neurons. To test this possibility, we used the light damage model to induce 
neuronal apoptosis of photoreceptor cells [25,27,55,56]. Our data shows no statistically 
significant differences in the number of apoptotic neurons after light induced neuronal 
damage, independent of the presence of Cre.  
  
There is evidence in the literature that tamoxifen treatment itself has unwanted side effects, 
e.g. cell death of retinal pigment epithelial (RPE) cells through caspase dependent and 
independent mechanisms [9]. Based on our results, we can exclude such potential side 
effects regarding an altered neuronal vulnerability, at least for the tamoxifen concentration 
and the application route used in our study. 
In summary, we conclude that the Cre-loxP system and its induction through tamoxifen is a 
safe and reliable method to delete desired target genes in the neuronal retina. Neither the 
expression of Cre, nor tamoxifen exposure itself, interferes with the maintenance of the 
neuronal tissues regarding neuronal morphology, function, the expression of molecular 
markers and neuronal vulnerability, as well as the reactivity of macro- and microglia cells. 
Our study might therefore reassure neuroscientists in using this method in the future. We 
also thoroughly characterized three widely used Cre lines, α-Cre, Lmop-Cre and the 
tamoxifen inducible CAGGCre-ERTM, which is a valuable resource for other scientists trying 
to find a Cre line with Cre expression patterns suitable for their specific research needs. 
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Figure legends 
Figure 1: Expression pattern and activity of the Cre recombinase in CAGGCre-ERTM, α-
Cre and Lmop-Cre mice. A. The intense β-galactosidase staining (upper right panel) 
throughout the eye in a four weeks old CAGGCre-ERTM/R26R mouse indicates a successful 
activation of Cre recombinase expression in ocular tissue following treatment with tamoxifen 
from postnatal day (P) 28-32. Scale bars correspond to 500 µm. The higher magnification of 
the β-galactosidase reaction (lower right panel) shows a homogenous staining in the retina 
and choroid of a four weeks old CAGGCre-ERTM/R26R mouse. The control littermate 
(control/R26R) does not show a positive reaction (left panel). Scale bars correspond to 50 
µm. B. The intense β-galactosidase staining (upper right panel) indicates the activity of the 
Cre recombinase in the neuronal retina and the non-pigmented epithelium of the ciliary body 
(arrows) in the eye of a ten days old α-Cre/R26R mouse. Scale bars correspond to 200 µm. 
The higher magnification of the β-galactosidase stained retina (lower right panel) shows an 
intense reaction in the neuronal layers of the retina in a ten days old α-Cre/R26R mouse. The 
control littermate (control/R26R) does not show a positive reaction (left panel). Scale bars 
correspond to 50 µm. C. The intense β-galactosidase staining (upper right panel) in the eye 
of a three weeks old Lmop-Cre/R26R mouse indicates the activity of the Cre recombinase in 
the ONL. Scale bars correspond to 200 µm. The detailed magnification of the β-
galactosidase reaction (lower right panel) shows a staining in the outer plexiform layer, ONL 
and the inner and outer segments of the photoreceptor cells of a three weeks old Lmop-
Cre/R26R mouse. The control littermate (control/R26R) does not show a positive reaction 
(left panel). Scale bars correspond to 50 µm. RGC. retinal ganglion cells; INL. inner nuclear 
layer; ONL. outer nuclear layer; RPE. retinal pigment epithelium. 
Figure 2: Retinal morphology and morphometric analysis of the INL and ONL in 
CAGGCre-ERTM, α-Cre, Lmop-Cre and control(TX) mice. A. Richardson stained semithin 
sections of an eight weeks old control(TX) (left) and its CAGGCre-ERTM (right) littermate 
retina. The retinal morphology does not show any obvious changes in the transgenic animal. 
B./C. Spider-diagrams reflecting the thickness of the INL (B) and ONL (C) of eight weeks old 
  
control(TX) and CAGGCre-ERTM animals. Tamoxifen treatment postnatal day (P) 28-32. Data 
are shown as mean ± SEM, n = 5/4, p > 0.05 (not significant), Student’s t-test. D. Richardson 
stained semithin section of a 6 weeks old control (left) and its α-Cre (right) littermate retina. 
The retinal morphology does not show any obvious changes in the transgenic animal. E./F. 
Spider-diagrams reflecting the thickness of the INL (E) and ONL (F) of six weeks old control 
and α-Cre animals. Data are shown as mean ± SEM, n = 7/5, p > 0.05 (not significant), 
Student’s t-test. G. Richardson stained semithin section of a ten weeks old control (left) and 
its Lmop-Cre (right) littermate retina. The retinal morphology does not show any obvious 
changes in the transgenic animal. H./I. Spider-diagrams reflecting the thickness of the INL 
(H) and ONL (I) of ten weeks old control and Lmop-Cre animals. Data are shown as mean ± 
SEM, n = 4/3, p > 0.05 (not significant), Student’s t-test. J. Richardson stained semithin 
section of a six weeks old control (left) and an eight weeks old tamoxifen treated control(TX) 
(right) retina. The retinal morphology does not show any obvious changes in the tamoxifen 
exposed animal. K./L. Spider-diagrams reflecting the thickness of the INL (K) and ONL (L) of 
control and tamoxifen treated animals. Tamoxifen treatment postnatal day (P) 28-32. Data 
are shown as mean ± SEM, n = 5/5, p > 0.05 (not significant), Student’s t-test. RGC. retinal 
ganglion cells; INL. inner nuclear layer; ONL. outer nuclear layer. 
Figure 3: In vivo angiography of CAGGCre-ERTM, α-Cre, Lmop-Cre and control(TX) 
mice. In vivo funduscopy and fluorescence angiography of six weeks old CAGGCre-ERTM 
(A) α-Cre (B) and Lmop-Cre (C) mice. The fundus is regular and the retinal vessels are well 
perfused with fluorescein (green) in the transgenic animals and not showing any obvious 
alterations compared to their respective controls. The same is true when control(TX) animals 
(panel A, left side) are compared to controls (panel B, left side). Tamoxifen treatment 
postnatal day (P) 28-32. 
Figure 4: In vivo electrography (ERG) analysis of CAGGCre-ERTM mice. Dark adapted 
ERGs in six weeks old transgenic CAGGCre-ERTM mice show similar waveforms (A) and a- 
and b-wave amplitudes and implicit times (B, C) compared to control(TX) indicating a regular 
  
rod function. After light adaptation again transgenic CAGGCre-ERTM mice show similar 
waveforms (D) and amplitudes (E) compared to wildtype littermates. Since the small implicit 
times difference (E) was not significant, our results indicate also a normal cone functions. 
Tamoxifen treatment postnatal day (P) 28-32. 
Figure 5: Microglia reactivity in the retinae of CAGGCre-ERTM, α-Cre, Lmop-Cre and 
control(TX) mice. Immunoreactivity for IBA1 (red) in the retina at six weeks of age. Distinct 
immunoreactivity for IBA1 (arrowheads) is detectable at the inner retinal surface and inner 
and outer plexiform layers of the CAGGCre-ERTM (A), α-Cre (C) and Lmop-Cre (D) and 
corresponding controls/control(TX). Nuclei are DAPI-stained (blue). The antibody control 
sections indicate the specificity of the immunohistochemical reaction. Tamoxifen treatment 
postnatal day (P) 28-32. RGC. retinal ganglion cell layer; INL. inner nuclear layer; ONL. outer 
nuclear layer; RPE. retinal pigment epithelium. B. Real-time RT-PCR for Cd68, Iba1, Egr1 
and Ccl2 mRNA in six weeks old CAGGCre-ERTM and corresponding control(TX) retinae and 
six to eight weeks old control and tamoxifen treated control(TX) retinae. Tamoxifen treatment 
postnatal day (P) 28-32. Data are means ± SEM. B: control(TX) n > 5, CAGGCre-ERTM n> 5, 
except for Cd68 n=3. control n ≥ 4, control(TX) n ≥4, except for Ccl2 n=3. p > 0.05 (not 
significant), Student’s t-test. AU: arbitrary unit. 
Figure 6: GFAP in the retinae of CAGGCre-ERTM, α-Cre, Lmop-Cre and control(TX) 
mice. Immunoreactivity for GFAP (red) in the retina at six weeks of age. Distinct 
immunoreactivity for GFAP (arrowheads) is detectable at the inner retinal surface of the 
CAGGCre-ERTM (A), α-Cre (C) and Lmop-Cre (E) and corresponding controls. Nuclei are 
DAPI-stained (blue). The antibody control sections indicate the specificity of the 
immunohistochemical reaction. Tamoxifen treatment postnatal day (P) 28-32. RGC. retinal 
ganglion cell layer; INL. inner nuclear layer; ONL. outer nuclear layer; RPE. retinal pigment 
epithelium. B./D./F. Real-time RT-PCR for Gfap mRNA in six weeks old CAGGCre-ERTM (B), 
α-Cre (D) and Lmop-Cre (F) and corresponding control retinae. Tamoxifen treatment 
postnatal day (P) 28-32. Data are means ± SEM. (B) control(TX) n = 5, CAGGCre-ERTM n= 
  
7; (D) control n = 6, α-Cre n = 6; (F) control n = 4, Lmop-Cre n = 4; . p > 0.05 (not significant), 
Student’s t-test. AU: arbitrary unit. 
Figure 7: Expression levels of neuroprotective factors in the retinae of CAGGCre-ERTM, 
α-Cre, Lmop-Cre and control(TX) mice. Real-time RT-PCR for Lif, Edn2 and Fgf2 mRNA in 
six to eight weeks old CAGGCre-ERTM (A), control(TX) (B), α-Cre (C) and Lmop-Cre (D) and 
corresponding control retinae. Tamoxifen treatment postnatal day (P) 28-32. Data are means 
± SEM. (A) control n ≥ 4, CAGGCre-ERTM n ≥ 5; (B) control n =5, control(TX) n =5 ; (C) 
control n = 6, α-Cre n = 6; (D) control n ≥ 3 , Lmop-Cre n = 4, except for Lif: n = 2. p > 0.05 
(not significant), Student’s t-test. AU: arbitrary unit. 
Figure 8: Neuronal vulnerability of CAGGCre-ERTM, α-Cre, Lmop-Cre and control(TX) 
mice following light exposure. TUNEL labeling (green) in six weeks old retinae 30h after 
light exposure. The images of the retinal hemispheres show the characteristic accumulation 
of TUNEL positive cells in the central parts of light exposed retinae (A./D./G.) The detailed 
magnifications (B./E./H.) of the central retinae show the localization of the TUNEL-positive 
cells (arrowheads) in the ONL. Nuclei are DAPI-stained (blue). OS. Ora serrata; ON. Optic 
nerve; INL. inner nuclear layer; ONL. outer nuclear layer; C./F./I. Number of TUNEL-positive 
cells/mm² ONL in light exposed CAGGCre-ERTM (C), α-Cre (F) and Lmop-Cre (I) and 
corresponding control retinae. Tamoxifen treatment postnatal day (P) 28-32. Data are mean 
± SEM. (C) control: n = 4, CAGGCre-ERTM: n = 5, p = 0.63; (F) control: n = 7, α-Cre: n = 5, p 
= 0.73; (I) control: n = 2, Lmop-Cre n = 2, p = 0.66. Student’s t-test. AU: arbitrary unit. 
 
  
  
Table 1. Primers used for quantitative real-time PCR amplification 
Gene Sequence forward Sequence reverse 
Gapdh 5’-TGTCCGTCGTGGATCTGAC-3’ 5’-CCTGCTTCACCACCTTCTTG-3’ 
Gnb2l 5’-TCTGCAAGTACACGGTCCAG-3’ 5’-ACGATGATAGGGTTGCTGCT-3’ 
Rpl32 5’-GCTGCCATCTGTTTTACGG-3’ 5’-TGACTGGTGCCTGATGAACT-3’ 
Lif 5’-AAACGGCCTGCATCTAAGG-3’ 5’-AGCAGCAGTAAGGGCACAAT-3’ 
Edn2 5’-ACCTCCTCCGAAAGCTGAG-3’ 5’-TTTCTTGTCACCTCTGGCTGTA-
3’ Fgf2 5’-CCAACCGGTACCTTGCTATG-3’ 5’-
CCAGTCGTTCAAAGAAGAAACAC-3’ Ccl2 5’-CATCCACGTGTTGGCTCA-3’ 5’-
GATCATCTTGCTGGTGAATGAGT-3’ Cd68 5’-
CTCTCTAAGGCTACAGGCTGCT-3’ 
5’-TCACGGTTGCAAGAG AACA-3’ 
Egr1 5’- CTATGA AC T A CACA-3’ 5’-TCGTTTGGCTGGGATAACTC-3’ 
Iba1 5’-GGATTTGCAGGGAGGAAAAG-
3’ 
5’-TGGGATCATCGAGGAATTG-3’ 
Gfap 5’-TCGAGATCGCCACCTACAG-3’ 5’-GTCTGTACAGGAATGGTGATGC-
3’ 
 
  
  
  
  
  
  
  
  
  
  
Cre recombinase expression or topical tamoxifen treatment do not affect 
retinal structure and function, neuronal vulnerability or glial reactivity in the 
mouse eye 
Highlights: 
• Cre or tamoxifen do not influence neuronal morphology and function 
• Cre or tamoxifen do not induce macro- and microglia cell reactivity  
• Expression of neuroprotective factors is not influenced by Cre or tamoxifen 
• Cre or tamoxifen do not alter neuronal vulnerability 
 
 
